GenSci & IsoTis shareholders approve merger:
This article was originally published in Clinica
99.9% of Canadian firm GenSci's shareholders and 99.75% of IsoTis's have voted in favour of the merger of Swiss-Dutch IsoTis and GenSci OrthoBiologics, of Irvine, California. The group is hoping to double its combined revenues and reach profitability by 2005. In the six months to the end of June 2003, the two companies had combined sales of $11.8m and a net loss of $12.6m. The transaction is expected to close on October 27, and is dependent on the California Bankruptcy Court approving GenSci OrthoBiologics' emergence from Chapter 11 bankruptcy protection.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.